share_log

Talaris Therapeutics Analyst Ratings

Talaris Therapeutics Analyst Ratings

塔拉里斯疗法分析师评级
Benzinga Analyst Ratings ·  2023/01/30 06:12
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
01/30/2023 795.52% HC Wainwright & Co. → $12 Reiterates → Buy
10/24/2022 795.52% HC Wainwright & Co. $18 → $12 Maintains Buy
10/20/2022 49.25% SVB Leerink $7 → $2 Maintains Market Perform
10/20/2022 1243.28% HC Wainwright & Co. → $18 Initiates Coverage On → Buy
09/09/2022 347.76% Morgan Stanley $8 → $6 Maintains Equal-Weight
07/05/2022 497.01% Morgan Stanley → $8 Downgrades Overweight → Equal-Weight
07/01/2022 422.39% SVB Leerink $21 → $7 Downgrades Outperform → Market Perform
05/24/2022 1392.54% Morgan Stanley $21 → $20 Maintains Overweight
05/13/2022 1467.16% SVB Leerink $22 → $21 Maintains Outperform
03/23/2022 1467.16% Morgan Stanley $20 → $21 Maintains Overweight
11/12/2021 1541.79% SVB Leerink $21 → $22 Maintains Outperform
06/01/2021 2511.94% Morgan Stanley → $35 Initiates Coverage On → Overweight
06/01/2021 1840.3% Guggenheim → $26 Initiates Coverage On → Buy
06/01/2021 2511.94% Evercore ISI Group → $35 Initiates Coverage On → Outperform
06/01/2021 1467.16% SVB Leerink → $21 Initiates Coverage On → Outperform
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
2023年1月30日 795.52% HC Wainwright公司 →$12 重申 →购买
10/24/2022 795.52% HC Wainwright公司 $18→$12 维护 买
10/20/2022 49.25% SVB Leerink $7→$2 维护 市场表现
10/20/2022 1243.28% HC Wainwright公司 →$18 开始承保 →购买
09/09/2022 347.76% 摩根士丹利 $8→$6 维护 等重
07/05/2022 497.01% 摩根士丹利 →$8 评级下调 超重→等重
07/01/2022 422.39% SVB Leerink $21→$7 评级下调 跑赢→市场表现
2022年05月24日 1392.54% 摩根士丹利 $21→$20 维护 超重
2022年05月13日 1467.16% SVB Leerink $22→$21 维护 跑赢大盘
03/23/2022 1467.16% 摩根士丹利 $20→$21 维护 超重
2021年11月12日 1541.79% SVB Leerink $21→$22 维护 跑赢大盘
06/01/2021 2511.94% 摩根士丹利 →$35 开始承保 →超重
06/01/2021 1840.3% 古根海姆 →$26 开始承保 →购买
06/01/2021 2511.94% Evercore ISI集团 →$35 开始承保 →跑赢大盘
06/01/2021 1467.16% SVB Leerink →$21 开始承保 →跑赢大盘

What is the target price for Talaris Therapeutics (TALS)?

Talaris Treeutics(TALS)的目标价格是多少？

The latest price target for Talaris Therapeutics (NASDAQ: TALS) was reported by HC Wainwright & Co. on January 30, 2023. The analyst firm set a price target for $12.00 expecting TALS to rise to within 12 months (a possible 795.52% upside). 10 analyst firms have reported ratings in the last year.

塔拉里斯治疗公司(纳斯达克：TALS)的最新目标价是由HC Wainwright&Co.于2023年1月30日报道的。这家分析公司将目标价定为12美元，预计总价值将在12个月内上升(可能上涨795.52%)。去年有10家分析公司公布了评级。

What is the most recent analyst rating for Talaris Therapeutics (TALS)?

Talaris Treeutics(TALS)的最新分析师评级是什么？

The latest analyst rating for Talaris Therapeutics (NASDAQ: TALS) was provided by HC Wainwright & Co., and Talaris Therapeutics reiterated their buy rating.

塔拉里斯治疗公司(纳斯达克代码：TALS)的最新分析师评级由HC Wainwright&Co.提供，塔拉里斯治疗公司重申了他们的买入评级。

When is the next analyst rating going to be posted or updated for Talaris Therapeutics (TALS)?

Talaris Treeutics(TALS)的下一次分析师评级将于何时发布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Talaris Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Talaris Therapeutics was filed on January 30, 2023 so you should expect the next rating to be made available sometime around January 30, 2024.

分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Talaris治疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Talaris治疗公司的上一次评级是在2023年1月30日提交的，所以你应该预计下一次评级将在2024年1月30日左右的某个时候提供。

Is the Analyst Rating Talaris Therapeutics (TALS) correct?

分析师对Talaris Treeutics(TALS)的评级正确吗？

While ratings are subjective and will change, the latest Talaris Therapeutics (TALS) rating was a reiterated with a price target of $0.00 to $12.00. The current price Talaris Therapeutics (TALS) is trading at is $1.34, which is within the analyst's predicted range.

虽然评级是主观的，并将发生变化，但最新的Talaris治疗(TALS)评级被重申，目标价在0.00美元至12.00美元之间。Talaris Treateutics(TALS)目前的交易价格为1.34美元，在分析师的预测范围内。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发